Respiratory adverse effects of opioids for breathlessness: a systematic review and meta-analysis
S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 26 . S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 27. S7 AND S26 RR: no change (no data shown) ADHF: acute decompensated heart failure; AIDS: acquired immune deficiency syndrome; AN: opioids on "as needed" basis; BO: bronchiolitis obliterans; CDPF: collagen disease-related pulmonary fibrosis; CHF: chronic heart failure; COPD: chronic obstructive pulmonary disease; IIP: idiopathic interstitial pneumonia; ILD: interstitial lung disease; IPF: idiopathic pulmonary fibrosis; IR: immediate-release opioids; MED: morphine equivalent dose; ORD: obstructive respiratory disease; PaCO2: partial pressure of arterial carbon dioxide; PaO2: partial pressure of arterial oxygen; PH: pulmonary hypertension; RD: respiratory depressions; RR: respiratory rate; RRD: restrictive respiratory disease; SaO2: arterial oxygen saturation; SR: sustained-release opioids 1 intervention is started on an as needed basis and transitioned to standing immediate-release opioids or sustained release opioids (with or without immediate-release opioids as needed) as tolerated; 2 application of opioid for breakthrough breathlessness possible 3 median change 7 [36] shown) Natalini, 2011 [37] At rest, arterial PSV-I: 6.27 (1.9)* PSV-C: 5.9 (1.9 
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